Bruker Corporation (NASDAQ:BRKR) Receives Average Recommendation of “Hold” from Brokerages

Bruker Corporation (NASDAQ:BRKR) has been given an average rating of “Hold” by the fifteen ratings firms that are currently covering the firm, Marketbeat Ratings reports. Two analysts have rated the stock with a sell rating, five have given a hold rating, seven have issued a buy rating and one has issued a strong buy rating on the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $50.3846.

BRKR has been the subject of a number of recent research reports. Bank of America boosted their price objective on Bruker from $43.00 to $60.00 and gave the stock a “buy” rating in a report on Monday, December 15th. TD Cowen cut their target price on Bruker from $53.00 to $43.00 and set a “hold” rating on the stock in a research report on Friday, February 13th. Zacks Research upgraded Bruker from a “strong sell” rating to a “hold” rating in a report on Monday, December 8th. Wolfe Research raised Bruker from a “peer perform” rating to an “outperform” rating and set a $60.00 price target for the company in a research report on Wednesday, December 10th. Finally, Jefferies Financial Group set a $50.00 price objective on Bruker in a research note on Thursday, February 12th.

Bruker Stock Performance

Shares of BRKR stock opened at $33.33 on Monday. The firm has a 50 day moving average of $41.57 and a 200-day moving average of $41.14. The company has a market cap of $5.07 billion, a price-to-earnings ratio of -222.17, a price-to-earnings-growth ratio of 2.00 and a beta of 1.19. The company has a quick ratio of 0.87, a current ratio of 1.73 and a debt-to-equity ratio of 0.75. Bruker has a 52 week low of $28.53 and a 52 week high of $56.22.

Bruker (NASDAQ:BRKR) last issued its earnings results on Thursday, February 12th. The medical research company reported $0.59 EPS for the quarter, missing the consensus estimate of $0.65 by ($0.06). Bruker had a negative net margin of 0.25% and a positive return on equity of 13.56%. The firm had revenue of $977.20 million during the quarter, compared to analyst estimates of $964.61 million. During the same quarter in the prior year, the business earned $0.76 earnings per share. The business’s quarterly revenue was down .2% on a year-over-year basis. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. On average, equities analysts forecast that Bruker will post 2.69 earnings per share for the current year.

Bruker Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, April 7th. Investors of record on Monday, March 23rd will be issued a dividend of $0.05 per share. This represents a $0.20 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date is Monday, March 23rd. Bruker’s dividend payout ratio (DPR) is -133.33%.

Insider Activity at Bruker

In other Bruker news, VP Mark Munch sold 2,000 shares of Bruker stock in a transaction dated Friday, March 13th. The shares were sold at an average price of $35.44, for a total value of $70,880.00. Following the sale, the vice president owned 128,443 shares of the company’s stock, valued at approximately $4,552,019.92. The trade was a 1.53% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In the last quarter, insiders sold 11,000 shares of company stock worth $554,280. Insiders own 27.30% of the company’s stock.

Hedge Funds Weigh In On Bruker

A number of institutional investors and hedge funds have recently added to or reduced their stakes in BRKR. Rockefeller Capital Management L.P. grew its stake in Bruker by 741.9% during the fourth quarter. Rockefeller Capital Management L.P. now owns 9,522 shares of the medical research company’s stock valued at $449,000 after acquiring an additional 8,391 shares in the last quarter. Mengis Capital Management Inc. increased its holdings in Bruker by 2.0% during the 4th quarter. Mengis Capital Management Inc. now owns 57,220 shares of the medical research company’s stock worth $2,696,000 after acquiring an additional 1,135 shares during the period. Pacer Advisors Inc. lifted its stake in Bruker by 42.8% in the 4th quarter. Pacer Advisors Inc. now owns 20,822 shares of the medical research company’s stock worth $981,000 after purchasing an additional 6,242 shares in the last quarter. Alberta Investment Management Corp purchased a new stake in Bruker in the 4th quarter worth approximately $1,748,000. Finally, Mercer Global Advisors Inc. ADV bought a new position in Bruker in the 4th quarter valued at $266,000. Institutional investors own 79.52% of the company’s stock.

Bruker Company Profile

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.